XML 75 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of the impact of stock-based compensation expense

The following presents the impact of stock-based compensation expense on our consolidated statements of income (in millions):

 

 

 

2024

 

 

2023

 

 

2022

 

Stock options

 

$

1.9

 

 

$

1.6

 

 

$

1.5

 

Restricted stock units

 

 

18.6

 

 

 

16.0

 

 

 

14.1

 

Employee Stock Purchase Plan

 

 

1.2

 

 

 

0.8

 

 

 

0.1

 

Total stock-based compensation

 

$

21.7

 

 

$

18.4

 

 

$

15.7

 

 

 

 

 

 

 

 

 

 

 

 

 

2024

 

 

2023

 

 

2022

 

Cost of product revenue

 

$

1.9

 

 

$

1.4

 

 

$

1.1

 

Selling, general and administrative

 

 

17.1

 

 

 

15.1

 

 

 

13.3

 

Research and development

 

 

2.7

 

 

 

1.9

 

 

 

1.3

 

Total stock-based compensation

 

$

21.7

 

 

$

18.4

 

 

$

15.7

 

Schedule of stock option activity

Stock option activity for the year ended December 31, 2024, is as follows:

 

 

 

Number of
Options

 

 

Weighted-
Average Price
Per Share

 

 

Weighted -
Average
Remaining
Contractual
Term (in Years)

 

 

Aggregate
Intrinsic Value
(in millions) (b)

 

Outstanding at December 31, 2023

 

 

967,560

 

 

$

37.78

 

 

 

3.7

 

 

$

35.5

 

Granted

 

 

128,099

 

 

 

66.40

 

 

 

 

 

 

 

Exercised (c)

 

 

(208,700

)

 

 

22.22

 

 

 

 

 

 

 

Forfeited/Expired

 

 

266

 

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2024

 

 

887,225

 

 

$

45.58

 

 

 

3.7

 

 

$

16.0

 

Exercisable at December 31, 2024

 

 

643,705

 

 

$

36.93

 

 

 

2.8

 

 

$

16.0

 

Exercisable and expected to vest at
   December 31, 2024 (a)

 

 

886,693

 

 

$

45.58

 

 

 

3.7

 

 

$

16.0

 

(a)
Represents the number of vested options at December 31, 2024, plus the number of unvested options at December 31, 2024, that are ultimately expected to vest based on our estimated forfeiture rate.
(b)
The aggregate intrinsic value is calculated as the positive difference between the exercise price of the underlying options and the quoted price of our common stock on December 31, 2024.
(c)
The total intrinsic value of options exercised was $12.0 million, $9.4 million and $10.7 million for the years ended December 31, 2024, 2023 and 2022, respectively.
Schedule of Unvested restricted stock unit activity

Restricted stock unit activity is presented below:

 

 

 

Shares
Subject to
Restriction

 

 

Weighted-
Average Grant
Date Fair
Value Per
Share

 

Outstanding at December 31, 2023

 

 

702,047

 

 

$

64.68

 

Granted

 

 

453,762

 

 

 

63.61

 

Vested (a)

 

 

(271,477

)

 

 

62.21

 

Forfeited

 

 

(31,094

)

 

 

65.59

 

Outstanding at December 31, 2024

 

 

853,238

 

 

$

64.91

 

The total fair value of restricted stock vested for the years ended December 31, 2024, 2023 and 2022 was $16.9 million, $17.8 million and $17.7 million, respectively.